Terumo Neuro
Terrence Callahan is an experienced professional in post-market surveillance and quality, with a career spanning over a decade in various leadership roles. Currently serving as Sr. Director of Post Market Surveillance at Terumo Neuro since January 2021, Terrence has also held the position of Director of Post Market Surveillance Quality at the same company. Prior experience includes serving as Sr. Director of Global Post Market Quality at JUUL Labs and Director of Post Market Surveillance & Vigilance at Terumo Medical Corporation. Earlier in the career, Terrence worked as Sr. Manager Global Post Market Regulatory at DePuy Synthes and was involved in post-market surveillance at Hill-Rom. Terrence holds a BA in Economics from Fairfield University and graduated from Fairfield Prep.
This person is not in any teams
This person is not in any offices
Terumo Neuro
1 followers
A global leader in neurovascular innovation, MicroVention is now Terumo Neuro. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care. We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica.